evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

20 questions · 20 findings · 3 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 15%Low 2 · 10%Moderate 10 · 50%High 5 · 25%

Febuxostat 80 mg/day vs placebo

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Serious adverse events · people with chronic gout

Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Serious adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa

It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review